Urotronic develops drug-coated balloon devices specifically designed for interventional urology, targeting benign prostatic hyperplasia (BPH) and urethral strictures. These devices deliver localized medication to reduce tissue obstruction and improve patient outcomes in urological procedures.
Funding
Funding not disclosed
Founders
Product
Problem
Benign prostatic hyperplasia (BPH) and urethral strictures cause tissue obstruction in the urinary tract, leading to lower urinary tract symptoms and requiring interventional urological procedures. Current treatments may not always provide long-term relief and can have associated side effects.
Solution
Urotronic develops drug-coated balloon (DCB) devices designed for interventional urology to treat BPH and urethral strictures. These devices deliver a localized dose of medication directly to the targeted tissue during a minimally invasive procedure. The drug inhibits cell proliferation and reduces inflammation, aiming to alleviate obstruction and improve urinary flow. This targeted drug delivery minimizes systemic exposure and potential side effects compared to oral medications. The Optilume BPH and Optilume for Strictures are examples of Urotronic's DCB technology.
Target Audience
The primary target audience includes urologists performing interventional procedures for BPH and urethral strictures, as well as patients seeking minimally invasive treatment options for these conditions.
Features
- Drug-coated balloon technology for localized drug delivery
- Minimally invasive procedure for treating BPH and urethral strictures
- Targeted drug delivery to reduce tissue obstruction
- Reduced systemic exposure and potential side effects
- Optilume BPH for treating benign prostatic hyperplasia
- Optilume for Strictures for treating urethral strictures